Biohaven Ltd. Payments of Stock Issuance Costs
Biohaven Ltd. (BHVN) reported Payments of Stock Issuance Costs of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsOfStockIssuanceCosts · last filed 2026-08-10
- Biohaven Ltd. payments of stock issuance costs for the quarter ending 2025-12-31 was $450.00K, a 66.67% decline year-over-year.
- Biohaven Ltd. payments of stock issuance costs for the quarter ending 2025-09-30 was $0.00.
- Biohaven Ltd. payments of stock issuance costs for the quarter ending 2024-12-31 was $1.35M, a 68.75% increase year-over-year.
- Biohaven Ltd. payments of stock issuance costs for the quarter ending 2024-09-30 was $0.00.
- Biohaven Ltd. payments of stock issuance costs for fiscal 2025 was $1.70M, a 21.07% decline from fiscal 2024.
- Biohaven Ltd. payments of stock issuance costs for fiscal 2024 was $2.15M, a 168.75% increase from fiscal 2023.
- Biohaven Ltd. payments of stock issuance costs for fiscal 2023 was $800.00K, a 20.00% decline from fiscal 2022.
- Biohaven Ltd. payments of stock issuance costs for fiscal 2022 was $1.00M.
| Period end | Payments of Stock Issuance Costs 3 month | Payments of Stock Issuance Costs 6 month | Payments of Stock Issuance Costs 9 month | Payments of Stock Issuance Costs 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-10 | |||
| 2025-12-31 | $450.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $450.00K derived: sum of 2 quarters · filed 2026-03-02 | $1.70M 10-K · filed 2026-03-02 | |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $1.25M 10-Q · filed 2025-11-10 | ||
| 2025-06-30 | $1.25M 10-Q · filed 2026-08-10 | |||
| 2024-12-31 | $1.35M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $1.35M derived: sum of 2 quarters · filed 2026-03-02 | $2.15M 10-K · filed 2026-03-02 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $800.00K 10-Q · filed 2025-11-10 | ||
| 2024-06-30 | $800.00K 10-Q · filed 2025-08-11 | |||
| 2023-12-31 | $800.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $800.00K derived: sum of 2 quarters · filed 2026-03-02 | $800.00K 10-K · filed 2026-03-02 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $0.00 10-Q · filed 2024-11-12 | ||
| 2023-06-30 | $0.00 10-Q · filed 2024-08-09 | |||
| 2022-12-31 | $1.00M 10-K · filed 2025-03-03 | |||
| 2021-12-31 | $0.00 10-K · filed 2024-02-29 | |||
| 2020-12-31 | $0.00 10-K · filed 2023-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |